Reuters
22 Sept 2026, 11:40 UTC · 7w ago
Celldex's skin disease drug meets goals in two late-stage trials
Impact · against what's priced in
Celldex Therapeutics is likely to see a positive price adjustment following the success of two late-stage trials for its skin disease drug. This clinical success significantly increases the probability of FDA filing and approval, providing a tangible catalyst for forward growth expectations.
- CLDX+0.80
No priced-in read yet
- In context
The drug meeting both primary and secondary goals in two late-stage trials provides a high-probability path toward FDA approval and commercialization.
Read from the article alone
Search tags
